Piper Sandler reiterates Merit Medical stock rating on growth outlook By Investing.com

Merit Medical Systems received a reiterated Overweight rating and $96 price target from Piper Sandler, implying meaningful upside from the $61.47 share price. The company also posted Q1 2026 EPS of $0.86 versus $0.83 expected and revenue of $381.9 million versus $377.8 million consensus, while management slightly raised 2026 revenue guidance and maintained EPS guidance. Piper Sandler highlighted solid execution, best-in-class operations, and a strong runway for EPS growth into 2026.

Analysis

MMSI’s setup is less about a single quarter and more about credibility compounding: when a medtech name can show margin upside while still preserving guide, the market usually rerates the duration of earnings rather than just the next print. That matters because the stock is likely still being valued as a “mixed execution” story, while management’s cadence is starting to look like a de-risked operating platform with multiple levers — mix, pricing, and OEM stabilization — that can support mid-teens EPS growth even if top-line growth stays only moderate.

The second-order winner is likely not just MMSI, but the broader small/mid-cap medtech group if investors start believing that discounted multiples are a function of sentiment rather than deteriorating fundamentals. If Piper’s view is right, competitors with similar gross margins but weaker execution should underperform, because this is the type of name that forces relative-value reallocations inside healthcare. The flip side is that any further evidence of recall-related leakage or integration friction on acquired assets could disproportionately hit the multiple, since the stock’s current upside case depends on continued operational cleanliness.

The key risk is timing: the market can wait months for 2026 acceleration, but it usually won’t pay up until the next two or three data points confirm that margin gains are repeatable. If revenue beats come without acceleration in organic growth, the stock can stall in a “good company, fair price” range despite strong fundamentals. A faster-than-expected rerate likely requires either another clean guide-up or visible evidence that new products and OEM are adding incremental growth without absorbing extra SG&A.

Consensus still seems anchored to valuation optics rather than quality of earnings. That creates a contrarian opportunity if the market is underestimating how much operating leverage is available from even low-single-digit growth, especially when the balance sheet is strong enough to absorb execution noise. The more interesting miss is that this may be an earnings-duration story, not a revenue-growth story, which tends to support a higher multiple than investors initially assign.

Key Decisions for Investors

• Initiate/add long MMSI over the next 1-2 weeks on any post-print or market weakness; target a rerate toward the low-$80s fair value zone over 3-6 months, with upside toward the analyst target if 2H execution stays clean.
• Pair trade: long MMSI / short a lower-quality medtech name with similar valuation but weaker margin trajectory; this isolates execution premium and should work over the next 2-3 quarters if margins remain stable.
• Buy near-dated call spreads in MMSI for the next earnings cycle if implied volatility is reasonable; use a defined-risk structure to capture a likely incremental guide-up without paying outright equity multiple expansion.
• Use any failure to show follow-through on organic growth or integration to trim 25-30% of the position; the downside case is a multiple compression back toward “solid operator, no catalyst” levels.